This activity is provided by Integrity Continuing Education, Inc.
Presented in partnership with the Medical Society of New Jersey.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continues to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Specific outstanding questions include those related to appropriate assessment for biologic selection, evaluation of efficacy, recognition of the need to switch or stop therapy, and effective long-term treatment. Join our esteemed faculty for an educational program targeted at answering these questions and optimizing use of biologic therapies in patients with moderate-to-severe asthma to improve health outcomes.
Reynold A. Panettieri, Jr., MD
Emeritus Professor of Medicine, University of Pennsylvania
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, New Jersey
This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form. Certificates will be sent via email within three weeks of receipt of the competed evaluation form.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, MedImmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi
The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you register or participate in an educational activity sponsored by Integrity Continuing Education, Inc. (Integrity CE), you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and… (continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
On the day of the webcast, you can access the event at this link: https://integrityce.com/nj-webcast
There are no fees for participating and receiving CME credit for this activity. For your participation, you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME Credit™. To do so, you must participate in the webcast and complete the posttest and evaluation following the event. A statement of credit will be issued via email within three weeks of submission of a completed activity evaluation form.